Home LiteratureArticle Details
PMID: 11752224 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response.

Molecular pharmacology ·Vol. 61 ·No. 1 ·2002-01-00 ·Pages 222-9

Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P

Abstract

(E)-2'-deoxy-2'-(fluoromethylene)cytidine (FMdC) is a new analog of deoxycytidine with promising anticancer activity. We investigated the action of FMdC on DNA metabolism by evaluating its incorporation into DNA, its excision from DNA in vitro, and the role of the incorporation of FMdC into DNA in causing cytotoxicity. In vitro DNA primer extension demonstrated that FMdC nucleotides were incorporated with relatively high substrate efficiency into the C sites of the elongating DNA strand. Once incorporated, FMdC became a poor substrate for further chain elongation by DNA polymerases, resulting in a termination of DNA synthesis at the sites of incorporation. Furthermore, the 3' --> 5' exonuclease activity of DNA polymerase epsilon or wild-type p53 protein was ineffective in removing the incorporated FMdC from DNA in vitro. FMdC also showed potent cytotoxic activity against human leukemia and solid tumor cells. Incubation with a low concentration of FMdC (10 nM) induced cell cycle arrest at S or G1 phases, but the cells eventually died as the time of incubation increased. Compared with HL-60 cells, human myeloid ML-1 cells with wild-type p53 were more sensitive to FMdC, but the S or G1 phase arrest did not seem to depend on the presence or absence of p53. Inhibiting the incorporation of FMdC into cellular DNA by aphidicolin suppressed the cytotoxic effect of the compound. We conclude that the incorporated FMdC nucleotide profoundly disrupts DNA synthesis and resists excision by exonucleases, and that incorporation of this analog into DNA is a key molecular event responsible for the drug's cytotoxicity.

MeSH Terms
Cell Cycle/drug effects DNA/drug effects,metabolism DNA Polymerase I/antagonists & inhibitors DNA Polymerase II/metabolism Deoxycytidine/analogs & derivatives,metabolism,pharmacology Flow Cytometry HL-60 Cells/drug effects,metabolism Humans Tumor Suppressor Protein p53/metabolism
Chemicals
Tumor Suppressor Protein p53 Deoxycytidine DNA DNA Polymerase I DNA Polymerase II tezacitabine
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Zhou Yan
Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Achanta Geetha
Pelicano Helene
Gandhi Varsha
Plunkett William
Huang Peng
Article Info
Journal
Molecular pharmacology
Abbr.
Mol Pharmacol
ISSN
0026-895X
Published
2002-01-00
Pages
222-9
Language
English
Region
United States
NLM ID
0035623
Subset
IM
Grants
NCI NIH HHS · CA16672 · United States
NCI NIH HHS · CA28596 · United States
NCI NIH HHS · CA77339 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com